Suggested remit: To appraise the clinical and cost effectiveness of avatrombopag within its marketing authorisation for treating chronic immune thrombocytopenia.
 
Status In progress
Process STA 2018
ID number 3838

Project Team

Project lead Shonagh D'Sylva

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Consultees

Companies sponsors Swedish Orphan Biovitrum (avatrombopag)
Others Department of Health and Social Care
  NHS Bromley CCG
  NHS England
  NHS North Lincolnshire CGG
  Welsh Government
Patient carer groups Genetic Alliance UK
  ITP Support Association
  Lymphoma Action
  South Asian Health Foundation
  Specialised Healthcare Alliance
  TTP Network
  AOFAC Foundation
Professional groups British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Society for Haematology
  British Society for Genetic Medicine
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
  UK Genetic Testing Network
  UK ITP Forum
  United Kingdom Cutaneous Lymphoma Group
  Immunodeficiency UK

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (mycophenolate mofetil)
  Accord UK (dapsone, mycophenolate mofetil)
  Amgen (romiplostim)
  Aspen (azathioprine)
  Dexcel Pharma (ciclosporin)
  Ennogen (azathioprine)
  Grifols (fostamatinib)
  Mylan (azathioprine, ciclosporin)
  Napp Pharmaceuticals (rituximab)
  Novartis Pharmaceuticals (ciclosporin, eltrombopag)
  Pfizer (rituximab)
  Roche (rituximab, mycophenolate mofetil)
  Rivopharm (dapsone)
  Sandoz (rituximab)
  Sanofi (danazol)
  Teva Pharma BV (mycophenolate mofetil)
  Tillomed Laboratories (azathioprine, dapsone, mycophenolate mofetil)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Hospital Information Services – Jehovah’s Witnesses
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  Cochrane Haematological Malignancies Group
  Lymphoma UK

Timeline

Key events during the development of the guidance:

Date Update
15 July 2021 Invitation to participate
15 July 2021 In progress. In progress
17 March 2021 Committee meeting: 1
03 February 2021 - 03 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance